115 related articles for article (PubMed ID: 16264153)
1. Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer.
Martin M; Vogel C; Crown J; Mackey J
JAMA; 2005 Nov; 294(17):2166; author reply 2166-7. PubMed ID: 16264153
[No Abstract] [Full Text] [Related]
2. Adjuvant docetaxel for node-positive breast cancer.
Noronha V
N Engl J Med; 2005 Sep; 353(9):954-5; author reply 954-5. PubMed ID: 16136712
[No Abstract] [Full Text] [Related]
3. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Martín M; Lluch A; Seguí MA; Ruiz A; Ramos M; Adrover E; Rodríguez-Lescure A; Grosse R; Calvo L; Fernandez-Chacón C; Roset M; Antón A; Isla D; del Prado PM; Iglesias L; Zaluski J; Arcusa A; López-Vega JM; Muñoz M; Mel JR
Ann Oncol; 2006 Aug; 17(8):1205-12. PubMed ID: 16766587
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy with TAC (docetaxel, doxorubicin, and cyclophosphamide) in patients with breast cancer--incidence of neutropenic fever outside clinical trials.
Passos-Coelho JL; Esteves S; Vieira PA; Isidoro M; Ribeiro M; Oliveira J; Moreira AR
Breast J; 2011; 17(5):539-41. PubMed ID: 21899649
[No Abstract] [Full Text] [Related]
5. Adjuvant docetaxel for node-positive breast cancer.
Ahluwalia MS; Daw HA
N Engl J Med; 2005 Sep; 353(9):954-5; author reply 954-5. PubMed ID: 16135845
[No Abstract] [Full Text] [Related]
6. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
7. Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.
Livi L; Meattini I; de Luca Cardillo C; Scotti V; Agresti B; Franzese C; Sanchez L; Nori J; Bertocci S; Cassani S; Bianchi S; Cataliotti L; Biti G
J Chemother; 2011 Feb; 23(1):36-9. PubMed ID: 21482493
[TBL] [Abstract][Full Text] [Related]
8. High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide.
Soong D; Haj R; Leung MG; Myers R; Higgins B; Myers J; Rajagopal S
J Clin Oncol; 2009 Sep; 27(26):e101-2. PubMed ID: 19652050
[No Abstract] [Full Text] [Related]
9. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.
Brain EG; Bachelot T; Serin D; Kirscher S; Graic Y; Eymard JC; Extra JM; Combe M; Fourme E; Noguès C; Rouëssé J;
JAMA; 2005 May; 293(19):2367-71. PubMed ID: 15900007
[TBL] [Abstract][Full Text] [Related]
10. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Wolowacz SE; Cameron DA; Tate HC; Bagust A
J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
13. [AIOM Conference 2004. Docetaxel: a recent conquest in the adjuvant therapy of breast cancer].
Adamo V
Tumori; 2004; 90(6):13-21. PubMed ID: 15762373
[No Abstract] [Full Text] [Related]
14. [Role of G-CSF for breast cancer chemotherapy].
Suzuki Y; Saito Y; Tokuda Y
Nihon Rinsho; 2007 Jun; 65 Suppl 6():572-4. PubMed ID: 17679213
[No Abstract] [Full Text] [Related]
15. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.
del Giglio A; Eniu A; Ganea-Motan D; Topuzov E; Lubenau H
BMC Cancer; 2008 Nov; 8():332. PubMed ID: 19014494
[TBL] [Abstract][Full Text] [Related]
16. Review of docetaxel/doxorubicin combination in metastatic breast cancer.
Diéras V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):31-3. PubMed ID: 9364539
[TBL] [Abstract][Full Text] [Related]
17. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
Ribas A; Albanell J; Bellmunt J; Solé-Calvo LA; Bermejo B; Gallardo E; Vidal R; Vera R; Eres N; Carulla J; Baselga J
J Clin Oncol; 1996 May; 14(5):1573-80. PubMed ID: 8622074
[TBL] [Abstract][Full Text] [Related]
18. [Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin].
Liutkauskiene S; Sveikata A; Juozaityte E; Characiejus D; Juodzbaliene E; Kregzdyte R; Fokas V
Medicina (Kaunas); 2009; 45(8):600-6. PubMed ID: 19773618
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer.
Montero A; Booser D; Esparza-Guerra L; Murray J; Rosales M; Hortobagyi G; Valero V
Drugs R D; 2005; 6(5):299-305. PubMed ID: 16128600
[No Abstract] [Full Text] [Related]
20. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]